Please assess the completion status of the following clinical trial:

Trial Title: Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~Each participant must meet all of the following inclusion criteria to be enrolled in the study:~* Multiple myeloma diagnosed according to the standard criteria.~* Participants with multiple myeloma who have relapsed following at least 2 lines of therapy.~* Participants must have measurable disease.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.~* Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse.~* Male participants who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse.~* Voluntary written consent.~* Suitable venous access for study-required blood sampling.~Exclusion Criteria:~Participants meeting any of the following exclusion criteria are not to be enrolled in the study:~* Peripheral neuropathy greater than or equal to (\>=) Grade 2.~* Female participants who are lactating or have a positive serum pregnancy test during the screening period.~* Major surgery within 14 days before the first dose of study drug.~* Infection requiring systemic antibiotic therapy or other serious infection within 14 days before the first dose of study treatment.~* Life-threatening illness unrelated to cancer.~* Diarrhea \> Grade 1, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) categorization.~* Systemic antineoplastic or radiation therapy within 14 days of cytotoxic agents within 21 days before the first dose of study treatment.~* Treatment with any investigational products within 21 days before the first dose of study treatment.~* Treatment with any investigational proteasome inhibitor.~* Systemic treatment with prohibited medication.~* Ongoing therapy with corticosteroids greater than 10mg of prednisone or its equivalent per day. Inhaled and topical steroids are permitted.~* Central nervous system involvement.~* Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months.~* Corrected QT interval (QTc) \> 470 milliseconds on a 12-lead electrocardiogram (ECG) obtained during the screening period.~* Known human immunodeficiency virus (HIV) positive, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection.~* Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol.~* Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption of tolerance of ixazomib including difficulty swallowing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation Cohort 1: Ixazomib 0.24 mg/m^2 (Type: EXPERIMENTAL): Ixazomib 0.24 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 220 days).
- Dose Escalation Cohort 2: Ixazomib 0.48 mg/m^2 (Type: EXPERIMENTAL): Ixazomib 0.48 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 270 days).
- Dose Escalation Cohort 3: Ixazomib 0.8 mg/m^2 (Type: EXPERIMENTAL): Ixazomib 0.8 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 137 days).
- Dose Escalation Cohort 4: Ixazomib 1.2 mg/m^2 (Type: EXPERIMENTAL): Ixazomib 1.2 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1436 days).
- Dose Escalation Cohort 5: Ixazomib 1.68 mg/m^2 (Type: EXPERIMENTAL): Ixazomib 1.68 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 456 days).
- Dose Escalation Cohort 6: Ixazomib 2.0 mg/m^2 (Type: EXPERIMENTAL): Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1621 days).
- Dose Escalation Cohort 7: Ixazomib 2.23 mg/m^2 (Type: EXPERIMENTAL): Ixazomib 2.23 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 2434 days).
- Relapsed and Refractory Expansion Cohort: Ixazomib 2 mg/m^2 (Type: EXPERIMENTAL): Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months, Participants must also be refractory to their most recent therapy as evidenced by PD while on therapy or within 60 days after their last dose of therapy (Up to 1621 days).
- Velcade-Relapsed (VR) Expansion Cohort: Ixazomib 2.0 mg/m^2 (Type: EXPERIMENTAL): Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after \>=1 prior therapy but have relapsed after previous Velcade exposure and were not treated with any other proteasome inhibitors (Up to 1573 days).
- Proteasome Inhibitor-Naive Expansion Cohort: Ixazomib 2 mg/m^2 (Type: EXPERIMENTAL): Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after \>=1 prior therapy which must include thalidomide (or lenalidomide) and corticosteroid, but who never received a proteasome inhibitor (Up to 550 days).
- Carfilzomib Expansion Cohort: Ixazomib 2.0 mg/m^2 (Type: EXPERIMENTAL): Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants who previously received carfilzomib and had relapsed or refractory disease (Up to 123 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete